Bone Safety Profile of Steroidal Aromatase Inhibitor in Comparison to Nonsteroidal Aromatase Inhibitors in Postmenopausal Women with Breast Cancer: A Network Meta-Analysis
Conclusion: A lower incidence of bone-related safety events was observed in patients treated with exemestane. (Source: Breast Care)
Source: Breast Care - February 18, 2022 Category: Cancer & Oncology Source Type: research
Simultaneous Method Development and Validation of Anastrozole along with Piperine: Degradation studies and degradants characterization using LC-QTOF-ESI-MS along with degradants in-silico ADMET predictions
CONCLUSION: Therefore, there is huge scope in the future to conduct pharmacological and formulation studies for this combination.PMID:35168518 | DOI:10.2174/1389200223666220215152606 (Source: Current Drug Metabolism)
Source: Current Drug Metabolism - February 16, 2022 Category: Drugs & Pharmacology Authors: K Jony Susanna Rahul Gajbhiye Bhaskar Sarmah Sachin Dattram Pawar Pakhuri Mehta Upadhyayula Suryanarayana Murty V Ravichandiran Amit Alexander Pramod Kumar Source Type: research
Simultaneous Method Development and Validation of Anastrozole along with Piperine: Degradation studies and degradants characterization using LC-QTOF-ESI-MS along with degradants in-silico ADMET predictions
CONCLUSION: Therefore, there is huge scope in the future to conduct pharmacological and formulation studies for this combination.PMID:35168518 | DOI:10.2174/1389200223666220215152606 (Source: Current Drug Metabolism)
Source: Current Drug Metabolism - February 16, 2022 Category: Drugs & Pharmacology Authors: K Jony Susanna Rahul Gajbhiye Bhaskar Sarmah Sachin Dattram Pawar Pakhuri Mehta Upadhyayula Suryanarayana Murty V Ravichandiran Amit Alexander Pramod Kumar Source Type: research
Simultaneous Method Development and Validation of Anastrozole along with Piperine: Degradation studies and degradants characterization using LC-QTOF-ESI-MS along with degradants in-silico ADMET predictions
CONCLUSION: Therefore, there is huge scope in the future to conduct pharmacological and formulation studies for this combination.PMID:35168518 | DOI:10.2174/1389200223666220215152606 (Source: Current Drug Metabolism)
Source: Current Drug Metabolism - February 16, 2022 Category: Drugs & Pharmacology Authors: K Jony Susanna Rahul Gajbhiye Bhaskar Sarmah Sachin Dattram Pawar Pakhuri Mehta Upadhyayula Suryanarayana Murty V Ravichandiran Amit Alexander Pramod Kumar Source Type: research
Simultaneous Method Development and Validation of Anastrozole along with Piperine: Degradation studies and degradants characterization using LC-QTOF-ESI-MS along with degradants in-silico ADMET predictions
CONCLUSION: Therefore, there is huge scope in the future to conduct pharmacological and formulation studies for this combination.PMID:35168518 | DOI:10.2174/1389200223666220215152606 (Source: Current Drug Metabolism)
Source: Current Drug Metabolism - February 16, 2022 Category: Drugs & Pharmacology Authors: K Jony Susanna Rahul Gajbhiye Bhaskar Sarmah Sachin Dattram Pawar Pakhuri Mehta Upadhyayula Suryanarayana Murty V Ravichandiran Amit Alexander Pramod Kumar Source Type: research
Simultaneous Method Development and Validation of Anastrozole along with Piperine: Degradation studies and degradants characterization using LC-QTOF-ESI-MS along with degradants in-silico ADMET predictions
CONCLUSION: Therefore, there is huge scope in the future to conduct pharmacological and formulation studies for this combination.PMID:35168518 | DOI:10.2174/1389200223666220215152606 (Source: Current Drug Metabolism)
Source: Current Drug Metabolism - February 16, 2022 Category: Drugs & Pharmacology Authors: K Jony Susanna Rahul Gajbhiye Bhaskar Sarmah Sachin Dattram Pawar Pakhuri Mehta Upadhyayula Suryanarayana Murty V Ravichandiran Amit Alexander Pramod Kumar Source Type: research
Abemaciclib in Combination With Endocrine Therapy for Patients With Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer: A Phase 1b Study
ConclusionsAbemaciclib in combination with multiple endocrine therapy options exhibited manageable safety and promising antitumor activity in patients with HR+, HER2- MBC.Clinical Trial Registrationhttps://clinicaltrials.gov/, identifier NCT02057133 (Source: Frontiers in Oncology)
Source: Frontiers in Oncology - February 10, 2022 Category: Cancer & Oncology Source Type: research
Approaches for Enhanced Extrapolation of Long-Term Survival Outcomes Using Electronic Health Records of Patients With Cancer
CONCLUSIONS: Our study leverages RWD to enhance long-term survival extrapolation. Future use cases should include applying patient eligibility criteria, weighting on baseline characteristics, and choice of time window to add RWD to trial data.PMID:35094796 | DOI:10.1016/j.jval.2021.08.013 (Source: Cancer Control)
Source: Cancer Control - January 31, 2022 Category: Cancer & Oncology Authors: Xiaoliang Wang Blythe J Adamson Andrew Briggs Katherine Tan Danielle Bargo Shuhag Ghosh Shrujal Baxi Scott Ramsey Source Type: research
Implication of body mass index (BMI) on the biological and clinical effects of endocrine therapy plus abemaciclib as neoadjuvant therapy for early breast cancer patients
ConclusionBMI categorized by the threshold of 25 did not significantly impact KI67% changes or clinical and radiological response. Although limited by the small sample size, these results are reassuring that the combination of abemaciclib plus anastrazole appears to be active in the early setting regardless of baseline BMI.Trial registration: ClinicalTrials.gov identifier: NCT02441946. (Source: Breast Cancer Research and Treatment)
Source: Breast Cancer Research and Treatment - January 25, 2022 Category: Cancer & Oncology Source Type: research
Health-related quality of life among elderly breast cancer patients treated with adjuvant endocrine therapy: a U.S Medicare population-based study
ConclusionAlthough there was no significant difference in physical HRQoL scores between AET agents, anastrozole and tamoxifen were associated with better mental HRQoL scores. (Source: Quality of Life Research)
Source: Quality of Life Research - January 22, 2022 Category: Health Management Source Type: research
POSC151 Cost-Effectiveness Analysis of Ribociclib in Ecuadorian Women with Advanced Breast Cancer
Estimate the cost-effectiveness of Ribociclib + ET compared to Letrozole, Palbociclib + ET, Fulvestrant, Anastrozole, Capacitabine and Tamoxifen, as the first line treatment for post menopausal patients with HR+, HER2- advanced breast cancer. (Source: Value in Health)
Source: Value in Health - January 1, 2022 Category: International Medicine & Public Health Authors: C Balmaceda, MA Espinoza, T Villacres Source Type: research
Simultaneous Quantification of Aromatase Inhibitors and Estrogens in Postmenopausal Breast Cancer Patients
CONCLUSIONS: We present here an assay suitable for the simultaneous measurement of serum levels of all third generation AIs and ultralow levels of estrogens, providing a powerful new tool to study drug efficacy and compliance. The method is highly valuable for postmenopausal patients whose pretreatment estradiol levels are below threshold of detection for most routine assays, but still require suppression.PMID:34958096 | DOI:10.1210/clinem/dgab923 (Source: Clinical Breast Cancer)
Source: Clinical Breast Cancer - December 27, 2021 Category: Cancer & Oncology Authors: Bj ørn-Erik Bertelsen Kristin Viste Thomas Helland Magnus Hagland H åvard Søiland J ürgen Geisler Tone Hoel Lende Per Eystein L ønning J ørn V Sagen Gunnar Mellgren Bj ørg Almås Source Type: research
Simultaneous Quantification of Aromatase Inhibitors and Estrogens in Postmenopausal Breast Cancer Patients
CONCLUSIONS: We present here an assay suitable for the simultaneous measurement of serum levels of all third generation AIs and ultralow levels of estrogens, providing a powerful new tool to study drug efficacy and compliance. The method is highly valuable for postmenopausal patients whose pretreatment estradiol levels are below threshold of detection for most routine assays, but still require suppression.PMID:34958096 | DOI:10.1210/clinem/dgab923 (Source: Clinical Genitourinary Cancer)
Source: Clinical Genitourinary Cancer - December 27, 2021 Category: Cancer & Oncology Authors: Bj ørn-Erik Bertelsen Kristin Viste Thomas Helland Magnus Hagland H åvard Søiland J ürgen Geisler Tone Hoel Lende Per Eystein L ønning J ørn V Sagen Gunnar Mellgren Bj ørg Almås Source Type: research
Simultaneous Quantification of Aromatase Inhibitors and Estrogens in Postmenopausal Breast Cancer Patients
CONCLUSIONS: We present here an assay suitable for the simultaneous measurement of serum levels of all third generation AIs and ultralow levels of estrogens, providing a powerful new tool to study drug efficacy and compliance. The method is highly valuable for postmenopausal patients whose pretreatment estradiol levels are below threshold of detection for most routine assays, but still require suppression.PMID:34958096 | DOI:10.1210/clinem/dgab923 (Source: The Journal of Clinical Endocrinology and Metabolism)
Source: The Journal of Clinical Endocrinology and Metabolism - December 27, 2021 Category: Endocrinology Authors: Bj ørn-Erik Bertelsen Kristin Viste Thomas Helland Magnus Hagland H åvard Søiland J ürgen Geisler Tone Hoel Lende Per Eystein L ønning J ørn V Sagen Gunnar Mellgren Bj ørg Almås Source Type: research
